We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
- Authors
Eberhard, David A; Johnson, Bruce E; Amler, Lukas C; Goddard, Audrey D; Heldens, Sherry L; Herbst, Roy S; Ince, William L; Jänne, Pasi A; Januario, Thomas; Johnson, David H; Klein, Pam; Miller, Vincent A; Ostland, Michael A; Ramies, David A; Sebisanovic, Dragan; Stinson, Jeremy A; Zhang, Yu R; Seshagiri, Somasekar; Hillan, Kenneth J
- Abstract
Epidermal growth factor receptor (EGFR) mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non-small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown. KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 25, p5900
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.02.857